These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 47195)

  • 21. Adverse effect of heparin in thrombin-antithrombin III interaction.
    Marciniak E
    Thromb Diath Haemorrh; 1975 Dec; 34(3):748-62. PubMed ID: 1209544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A differential effect of low-affinity heparin on the inhibition of thrombin and factor Xa by antithrombin.
    Nordenman B; Nordling K; Björk I
    Thromb Res; 1980 Feb 1-15; 17(3-4):595-600. PubMed ID: 7368180
    [No Abstract]   [Full Text] [Related]  

  • 23. Role of heparin in the inactivation of thrombin, factor Xa, and plasmin by antithrombin III.
    Stürzebecher J; Markwardt F
    Thromb Res; 1977 Dec; 11(6):835-46. PubMed ID: 146278
    [No Abstract]   [Full Text] [Related]  

  • 24. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
    Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
    Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antithrombin III, heparin cofactor and antifactor Xa in a clinical material.
    Odegård OR; Teien AN
    Thromb Res; 1976 Feb; 8(2):173-8. PubMed ID: 56054
    [No Abstract]   [Full Text] [Related]  

  • 27. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment.
    Bratt G; Törnebohm E; Lockner D; Bergström K
    Thromb Haemost; 1985 Apr; 53(2):208-11. PubMed ID: 4024029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.
    Lämmle B; Griffin JH
    Clin Haematol; 1985 Jun; 14(2):281-342. PubMed ID: 2994929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bothrojaracin: a potent two-site-directed thrombin inhibitor.
    Arocas V; Zingali RB; Guillin MC; Bon C; Jandrot-Perrus M
    Biochemistry; 1996 Jul; 35(28):9083-9. PubMed ID: 8703912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factor X.
    Jackson CM
    Prog Hemost Thromb; 1984; 7():55-109. PubMed ID: 6397768
    [No Abstract]   [Full Text] [Related]  

  • 31. Antithrombin III, the major modulator of intravascular coagulation, is synthesized by human endothelial cells.
    Chan TK; Chan V
    Thromb Haemost; 1981 Aug; 46(2):504-6. PubMed ID: 7302889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Inhibitory effect of plasmin prothrombin cleavage products in relation to thrombin and active factor X].
    Mirkamalova EG; Baskova IP
    Dokl Akad Nauk SSSR; 1978; 239(4):977-9. PubMed ID: 148355
    [No Abstract]   [Full Text] [Related]  

  • 33. Activation of factor X and prothrombin in antithrombin-III depleted plasma: the effects of heparin.
    Ofosu FA; Blajchman MA; Modi G; Cerskus AL; Hirsh J
    Thromb Res; 1981 Aug 15-Sep 1; 23(4-5):331-45. PubMed ID: 7324001
    [No Abstract]   [Full Text] [Related]  

  • 34. A new low molecular weight heparin fragment (PK 10169): in vitro and in vivo studies.
    Vinazzer H; Woler M
    Haemostasis; 1986; 16(2):106-15. PubMed ID: 2423420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma.
    Andersson LO; Barrowcliffe TW; Holmer E; Johnson EA; Söderström G
    Thromb Res; 1979; 15(3-4):531-41. PubMed ID: 494159
    [No Abstract]   [Full Text] [Related]  

  • 36. The conversion of prothrombin to thrombin. II. Differentiation between thrombin- and factor Xa-catalyzed proteolyses.
    Esmon CT; Owen WG; Jackson CM
    J Biol Chem; 1974 Jan; 249(2):606-11. PubMed ID: 4809531
    [No Abstract]   [Full Text] [Related]  

  • 37. A new low molecular weight heparin fragment (PK 10169): in vitro and in vivo studies.
    Vinazzer H; Woler M
    Thromb Res; 1985 Oct; 40(2):135-46. PubMed ID: 3878009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inherited AT-III deficiency: fast and slow inactivation of thrombin and factor Xa.
    Mortensen JZ
    Thromb Res; 1984 Mar; 33(5):511-5. PubMed ID: 6719397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The rabbit as an animal model for the activated factor X-antithrombin III-heparin reaction.
    Gitel SN; Wessler S; Medina VM
    Circ Res; 1977 Aug; 41(2):187-91. PubMed ID: 872292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma antithrombin III: a quantitative assay of biological activity.
    Gitel SA; Wessler S
    Thromb Res; 1975 Jul; 7(1):5-16. PubMed ID: 1154342
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.